Profits lag behind sales growth at Disetronic
This article was originally published in Clinica
The net income of the Swiss drug delivery company, Disetronic went up by 10% to reach SwFr22 million ($15 million), in the year ended March 31, while total sales increased by 29% to SwFr132 million. The company, of Burgdorf, said that the disproportionately small growth in net income, compared with sales growth, was due to a more conservative investment policy and the currency movements.
You may also be interested in...
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.
The UK's MHRA is looking for manufacturers to submit COVID-19 self-tests that meet minimum and desired criteria for evaluation, after finding its recently purchased 3.5m self-tests failed to meet these standards. Criteria include no requirement for testing knowledge or training or assistance from a healthcare professional in administering or interpreting the results of the test, as well as a 95% accuracy level.